# US 2010/0167261 A1 · Platelet stabilization > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2010/0167261 A1 - Document ID: US20100167261A1 - Status: Published application - Kind: A1 - Application number: 12/280,027 - Filed: 2007-02-20 - Published: 2010-07-01 - Earliest claimed: 2006-02-21 - Assignees: Siemens Healthcare Diagnostics Inc. - Inventors: Josep Maria Jou; Maribel Diaz-Ricart; Gines Escolar - Web page: https://patentgrep.com/patent/US20100167261A1 ## CPC - A01N 1/126: Physiologically active agents, e.g. antioxidants or nutrients - A01N 1/10: Preservation of living parts - A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00) - A61K 31/366: having six-membered rings, e.g. delta-lactones - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - G01N 33/86: involving blood coagulating time {or factors, or their receptors} - A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract Provided are methods for stabilizing mean platelet component and/or platelets in a sample comprising combining said sample with EDTA, a second anticoagulant, and one or more kinase inhibitors. Also provided are compositions for stabilizing a sample comprising platelets, and kits for storing a platelet sample. ## Claims ### Claim 1 A method comprising: combining a sample comprising platelets with an anticoagulant comprising EDTA and one or more kinase inhibitors, thereby forming a combination, wherein the platelets of said sample are stabilized. ### Claim 2 (depends on 1) The method according to claim 1 wherein at least one of said one or more kinase inhibitors is a phosphatidylinositol kinase inhibitor. ### Claim 3 (depends on 1) The method according to claim 1 wherein said one or more kinase inhibitors comprises wortmanin. ### Claim 4 (depends on 1) The method according to claim 1 wherein said one or more kinase inhibitors comprises tyrphostin. ### Claim 5 (depends on 1) The method according to claim 1 wherein said one or more kinase inhibitors comprises wortmanin and tyrphostin. ### Claim 6 (depends on 5) The method according to claim 5 wherein the final concentration of wortmanin in said combination is about 1 μM and the final concentration of tyrphostin in said combination is about 50 μM. ### Claim 7 (depends on 1) The method according to claim 1 wherein said combination further comprises a second anticoagulant. ### Claim 8 (depends on 7) The method according to claim 7 wherein said second anticoagulant comprises citrate. ### Claim 9 (depends on 7) The method according to claim 7 wherein said second anticoagulant comprises citrate, phosphate, and dextrose. ### Claim 10 (depends on 9) The method according to claim 9 wherein said citrate comprises trisodium citrate 2H2O and citric acid H2O. ### Claim 11 (depends on 9) The method according to claim 9 wherein said phosphate comprises sodium hydrogen phosphate. ### Claim 12 (depends on 10) The method according to claim 10 wherein the final concentration of said trisodium citrate 2H2O in said combination is about 1.1 mM and the final concentration of said citric acid H2O in said combination is about 0.2 mM. ### Claim 13 (depends on 11) The method according to claim 11 wherein the final concentration of said sodium hydrogen phosphate in said combination is about 0.2 mM. ### Claim 14 (depends on 9) The method according to claim 9 wherein the final concentration of said dextrose in said combination is about 0.8 mM. ### Claim 15 (depends on 1) The method according to claim 1 further comprising storing said sample at a temperature of about 22° C. ### Claim 16 (depends on 1) The method according to claim 1 comprising storing said sample for up to about six hours. ### Claim 17 (depends on 1) The method according to claim 1 comprising storing said sample for up to about 24 hours. ### Claim 18 (depends on 1) The method according to claim 1 further comprising storing said sample at a temperature of about 4° C. ### Claim 19 (depends on 18) The method according to claim 18 comprising storing said sample for up to about six hours. ### Claim 20 (depends on 18) The method according to claim 18 comprising storing said sample for up to about 24 hours. ### Claim 21 (depends on 1) The method according to claim 1 wherein said EDTA comprises tripotassium EDTA. ### Claim 22 (depends on 1) The method according to claim 1 further comprising measuring mean platelet component of said stabilized sample. ### Claim 23 (depends on 1) The method according to claim 1 further comprising measuring the number of alpha granules of said stabilized sample. ### Claim 24 (depends on 1) The method according to claim 1 further comprising measuring the number of dense bodies of said stabilized sample. ### Claim 25 (depends on 1) The method according to claim 1 wherein said sample comprises blood. ### Claim 26 (depends on 1) The method according to claim 1 wherein stabilization of platelets comprises stabilization of mean platelet component. ### Claim 27 (depends on 1) The method according to claim 1 wherein stabilization of platelets comprises stabilization of mean platelet volume. ### Claim 28 (depends on 1) The method according to claim 1 wherein stabilization of platelets comprises stabilization of P-selectin expression. ### Claim 29 (depends on 1) The method according to claim 1 wherein stabilization of platelets comprises stabilization of platelet morphology. ### Claim 30 (depends on 29) The method according to claim 29 wherein said stabilization of platelet morphology comprises stabilization of one or both of α-granules and dense bodies. ### Claim 31 A composition for stabilizing a sample comprising platelets comprising an anticoagulant comprising EDTA and one or more kinase inhibitors. ### Claim 32 (depends on 31) The composition according to claim 31 wherein at least one of said one or more kinase inhibitors is a phosphatidylinositol kinase inhibitor. ### Claim 33 (depends on 31) The composition according to claim 31 wherein said one or more kinase inhibitors comprises wortmanin. ### Claim 34 (depends on 31) The composition according to claim 31 wherein said one or more kinase inhibitors comprises tyrphostin. ### Claim 35 (depends on 31) The composition according to claim 31 wherein said one or more kinase inhibitors comprises wortmanin and tyrphostin. ### Claim 36 (depends on 31) The composition according to claim 31 wherein said combination further comprises a second anticoagulant. ### Claim 37 (depends on 36) The composition according to claim 36 wherein said second anticoagulant comprises citrate. ### Claim 38 (depends on 36) The composition according to claim 36 wherein said second anticoagulant comprises citrate, phosphate, and dextrose. ### Claim 39 (depends on 38) The composition according to claim 38 wherein said citrate comprises trisodium citrate 2H2O and citric acid H2O. ### Claim 40 (depends on 38) The composition according to claim 38 wherein said phosphate comprises sodium hydrogen phosphate. ### Claim 41 (depends on 31) The composition according to claim 31 wherein said EDTA comprises tripotassium EDTA. ### Claim 42 A kit for storing a sample comprising platelets, said kit comprising: a vessel for said sample; and, storage reagents including an anticoagulant comprising EDTA and one or more kinase inhibitors. ### Claim 43 (depends on 42) The kit according to claim 42 wherein said anticoagulant comprising EDTA comprises tripotassium EDTA. ### Claim 44 (depends on 42) The kit according to claim 42, further comprising a second anticoagulant. ### Claim 45 (depends on 44) The kit according to claim 44 wherein said second anticoagulant comprises citrate. ### Claim 46 (depends on 44) The kit according to claim 44 wherein said anticoagulant comprises citrate, phosphate, and dextrose. ### Claim 47 (depends on 46) The kit according to claim 46 wherein said citrate comprises trisodium citrate 2H2O and citric acid H2O. ### Claim 48 (depends on 46) The kit according to claim 46 wherein said phosphate comprises sodium hydrogen phosphate. ### Claim 49 (depends on 42) The kit according to claim 42 wherein at least one of said one or more kinase inhibitors is a phosphatidylinositol kinase inhibitor. ### Claim 50 (depends on 42) The kit according to claim 42 wherein said one or more kinase inhibitors comprises wortmanin. ### Claim 51 (depends on 42) The kit according to claim 42 wherein said one or more kinase inhibitors comprises tyrphostin. ### Claim 52 (depends on 42) The kit according to claim 42 wherein said one or more kinase inhibitors comprises wortmanin and tyrphostin. ### Claim 53 (depends on 42) The kit according to claim 42 further comprising instructions for using said kit.